CONCLUSIONS: This paper delves into the significance of accurately measured glomerular filtration rate (mGFR) in clinical practice, highlighting its essential role in guiding medical decisions and managing kidney health, particularly in the context of renal cancer (RC) patients undergoing nephrotoxic anti-cancer drugs. The limitations and advantages of traditional glomerular filtration rate (GFR) estimation methods, primarily using serum biomarkers like creatinine and cystatin C, are discussed, emphasizing their possible inadequacy in cancer patients. Specifically, newer formulae designed for GFR estimation in cancer patients may not perform at best in RC patients. The paper explores various methods for direct GFR measurement, including the gold standard inulin clearance and alternatives like iohexol plasma clearance.
CONCLUSIONS: Despite the logistical challenges of these methods, their implementation is crucial for accurate renal function assessment. The paper concludes by emphasizing the need for continued research and innovation in GFR measurement methodologies to improve patient outcomes, particularly in populations with complex medical needs.
结论:本文深入研究了准确测量肾小球滤过率(mGFR)在临床实践中的意义,强调其在指导医疗决策和管理肾脏健康方面的重要作用,特别是在接受肾毒性抗癌药物的肾癌(RC)患者中。传统GFR估计方法的局限性和优点,主要使用血清生物标志物,如肌酐和胱抑素C,讨论,强调他们在癌症患者中可能的不足。具体来说,为癌症患者GFR估算而设计的较新公式在RC患者中可能效果不佳.本文探讨了直接测量GFR的各种方法,包括金标准菊粉清除率和碘海醇血浆清除率等替代品。
结论:尽管这些方法在后勤方面存在挑战,它们的实施对于准确评估肾功能至关重要。本文最后强调需要继续研究和创新的GFR测量方法,以改善患者的结果,特别是在有复杂医疗需求的人群中。